Sarepta rises as Pfizer ‘disappointing’ DMD results remove competitor overhang - InvestingChannel

Sarepta rises as Pfizer ‘disappointing’ DMD results remove competitor overhang

Shares of Sarepta Therapeutics (SRPT) are on the rise on Thursday after Pfizer (PFE) announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy, or DMD, did not meet its primary endpoint. Commenting on the… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3933230/-Sarepta-rises-as-Pfizer-disappointing-DMD-results-remove-competitor-overhang)

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire